Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism
A benign hematology article, not a large study but an eye opener.
A benign hematology article, not a large study but an eye opener.
Oleclumab (MEDI9447) is a human IgG1λ mAb that inhibits the function of cluster of differentiation 73 (CD73).8 CD73 is an enzyme found on the surfaces of cancer and immune cells and is involved in conversion of adenosine monophosphate to extracellular adenosine, which has an immunosuppressive effect on the tumor environment.9 CD73 upregulation by tumors has been shown to increase extracellular adenosine production and result in subsequent local immunosuppression in multiple canc
Another use of genomic testing in prostate cancer, pts with high risk mutation may need systemic therapy in addition to oligometastatic stereotactic radiotherapy, well informed patients with no high risk mutation signature may elect to go under surveillance to avoid side effects of androgen deprivation therapy, this also emphasizes the importance of genomic testing in personalizing pt’s care.
Another option for HR+ /HER-2 negative pts who failed hormonal therapies, caution to toxicity though esp neutropenia and diarrhea, no OS data yet, will be interesting to know if it worth the adverse events at this stage of disease.
Supportive care trial though negative. No role for high dose steroids here.
A radiation oncology article, would like to hear comments from our colleagues regarding this, It seems the trend in rad onc that shorter course is better.
Another prognostic marker that can predict added efficacy of therapy in this case bevacizumab.
Coming soon to a pharmacy near you?
Confirming that RR can be an alternative to R chemotherapy as a first line therapy in advanced stage follicular lymphoma.
Interesting food for thought in this ethnic group regarding TTP. Large retrospective review of the TTP registry showing that among races there was no variation in mortality, however African-Americans had a reduced RFS in all metrics. Rituximab was not helpful in 1L therapy in any group. In the 2L setting, Rituximab had a significant RFS benefit in Caucasians but not in African-Americans. It did not seem that access to care was the driver in reduced RFS. African-American’s may also have shorter-lived B-cell depletion from CD20-MAb therapy.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |